PROTALIX BIOTHERAPEUTICS INC (PLX)

US74365A3095 - Common Stock

1.27  -0.06 (-4.51%)

After market: 1.28 +0.01 (+0.79%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to PLX. PLX was compared to 594 industry peers in the Biotechnology industry. PLX has an average financial health and profitability rating. PLX is growing strongly while it is still valued neutral. This is a good combination! These ratings would make PLX suitable for growth investing!



6

1. Profitability

1.1 Basic Checks

In the past year PLX was profitable.
PLX had a negative operating cash flow in the past year.
PLX had negative earnings in each of the past 5 years.
In the past 5 years PLX always reported negative operating cash flow.

1.2 Ratios

PLX has a Return On Assets of 12.13%. This is amongst the best in the industry. PLX outperforms 97.63% of its industry peers.
Looking at the Return On Equity, with a value of 27.76%, PLX belongs to the top of the industry, outperforming 97.97% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 24.25%, PLX belongs to the top of the industry, outperforming 99.49% of the companies in the same industry.
Industry RankSector Rank
ROA 12.13%
ROE 27.76%
ROIC 24.25%
ROA(3y)-24.59%
ROA(5y)-31.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 16.69%, PLX belongs to the best of the industry, outperforming 96.95% of the companies in the same industry.
With an excellent Operating Margin value of 21.33%, PLX belongs to the best of the industry, outperforming 97.29% of the companies in the same industry.
PLX has a Gross Margin of 74.02%. This is amongst the best in the industry. PLX outperforms 84.41% of its industry peers.
PLX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 21.33%
PM (TTM) 16.69%
GM 74.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.75%
GM growth 5Y16.23%

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PLX is creating value.
There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -3.18, we must say that PLX is in the distress zone and has some risk of bankruptcy.
PLX has a Altman-Z score of -3.18. This is comparable to the rest of the industry: PLX outperforms 42.88% of its industry peers.
There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.18
ROIC/WACC2.64
WACC9.18%

2.3 Liquidity

A Current Ratio of 1.67 indicates that PLX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.67, PLX is doing worse than 81.19% of the companies in the same industry.
PLX has a Quick Ratio of 1.18. This is a normal value and indicates that PLX is financially healthy and should not expect problems in meeting its short term obligations.
PLX's Quick ratio of 1.18 is on the low side compared to the rest of the industry. PLX is outperformed by 86.61% of its industry peers.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.18

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 113.16% over the past year.
Looking at the last year, PLX shows a very strong growth in Revenue. The Revenue has grown by 33.77%.
PLX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.71% yearly.
EPS 1Y (TTM)113.16%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q42.86%
Revenue 1Y (TTM)33.77%
Revenue growth 3Y-4.5%
Revenue growth 5Y17.71%
Revenue growth Q2Q-27.05%

3.2 Future

Based on estimates for the next years, PLX will show a very strong growth in Earnings Per Share. The EPS will grow by 59.75% on average per year.
Based on estimates for the next years, PLX will show a very strong growth in Revenue. The Revenue will grow by 41.30% on average per year.
EPS Next Y126.92%
EPS Next 2Y54.01%
EPS Next 3Y59.75%
EPS Next 5YN/A
Revenue Next Year41.73%
Revenue Next 2Y17.32%
Revenue Next 3Y41.3%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

6

4. Valuation

4.1 Price/Earnings Ratio

PLX is valuated quite expensively with a Price/Earnings ratio of 25.40.
Based on the Price/Earnings ratio, PLX is valued cheaply inside the industry as 95.93% of the companies are valued more expensively.
PLX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.68.
With a Price/Forward Earnings ratio of 8.67, the valuation of PLX can be described as very reasonable.
Based on the Price/Forward Earnings ratio, PLX is valued cheaply inside the industry as 99.15% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.14. PLX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 25.4
Fwd PE 8.67

4.2 Price Multiples

98.31% of the companies in the same industry are more expensive than PLX, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 6.57

4.3 Compensation for Growth

PLX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PLX may justify a higher PE ratio.
A more expensive valuation may be justified as PLX's earnings are expected to grow with 59.75% in the coming years.
PEG (NY)0.2
PEG (5Y)N/A
EPS Next 2Y54.01%
EPS Next 3Y59.75%

0

5. Dividend

5.1 Amount

No dividends for PLX!.
Industry RankSector Rank
Dividend Yield N/A

PROTALIX BIOTHERAPEUTICS INC

NYSEARCA:PLX (3/18/2024, 8:04:01 PM)

After market: 1.28 +0.01 (+0.79%)

1.27

-0.06 (-4.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap92.65M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 25.4
Fwd PE 8.67
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.2
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.13%
ROE 27.76%
ROCE
ROIC
ROICexc
ROICexgc
OM 21.33%
PM (TTM) 16.69%
GM 74.02%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.67
Quick Ratio 1.18
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)113.16%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y126.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)33.77%
Revenue growth 3Y-4.5%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y